March 2012
Volume 53, Issue 14
Free
ARVO Annual Meeting Abstract  |   March 2012
Healaflow™ For The Modulation Of Postoperative Healing After Deep Sclerectomy
Author Affiliations & Notes
  • Michael Feusier
    Glaucoma Center, Montchoisi Clinic, Lausanne, Switzerland
  • Sylvain Roy
    Glaucoma Unit, Swiss Fed Inst of Technology, Lausanne, Switzerland
  • Alexandre Rizatto
    Glaucoma Center, Montchoisi Clinic, Lausanne, Switzerland
  • André Mermoud
    Glaucoma Center, Montchoisi Clinic, Lausanne, Switzerland
  • Footnotes
    Commercial Relationships  Michael Feusier, None; Sylvain Roy, Anteis SA, Plan-les-Ouates, Switzerland (C); Alexandre Rizatto, Anteis SA, Plan-les-Ouates, Switzerland (R); André Mermoud, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science March 2012, Vol.53, 2497. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Michael Feusier, Sylvain Roy, Alexandre Rizatto, André Mermoud; Healaflow™ For The Modulation Of Postoperative Healing After Deep Sclerectomy. Invest. Ophthalmol. Vis. Sci. 2012;53(14):2497.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : To evaluate the effect of a double cross-linked hyaluronic acid on the healing process control after deep sclerectomy surgery.

Methods: : Classical deep sclerectomy (DS) was performed between January and June 2010. The main diagnoses were primary open angle glaucoma, primary angle closure glaucoma and pseudoexfoliation. Surgeries were performed using Healaflow™ and results were compared against the same surgeries (DS) using collagen implant. The outcomes were the intraocular pressure (IOP), the number of antiglaucoma medication, and the number of complications and bleb management.

Results: : For the group with Healaflow™ (n=13) the mean age at surgery was 60.1 ± 10.9 years, the mean follow-up was 9.2 ± 2.1 months, the mean preoperative IOP was 19.8 ± 4.8 mmHg, and the mean number of antiglaucoma medication was 3.0 ± 1.0. At final follow-up visits, the mean IOP was 11.4 ± 3.8 mmHg (p<0.05), the mean number of antiglaucoma medication was 0.2 ± 0.4 (p<0.005), with 6 complications (5 bleb leaks, 1 iris incarceration). Nd:YAG goniopuncture was performed on 7 eyes, and needling of the filtering bleb was done on 5 eyes. No eye required further surgery. In the group with collagen implant (n=17) the mean age at surgery was 63.1 ± 11.0 years, the mean follow-up was 12.5 ± 2.4 months, the mean preoperative IOP was 18.5 ± 3.4 mmHg, and the mean number of antiglaucoma medication was 2.2 ± 1.2. At final follow-up visits, the mean IOP was 11.4 ± 3.4 mmHg (p<0.05), the mean number of antiglaucoma medication was 0.4 ± 0.7 (p<0.005), with 3 complications (1 bleb leak, 2 perforations). Nd:YAG goniopuncture was performed on 11 eyes, needling of the filtering bleb on 10 eyes. Two eyes required further surgical revision of the filtering site. Complete and overall success rates were 85% and 92%, respectively, in the Healaflow™ group, while rates were 71% and 88%, respectively, in the DS group.

Conclusions: : The slow resorbable highly crosslinked sodium hyaluronate drainage implant Healaflow™ prevents the postoperative filtering bleb fibrosis and helps in maintaining a functional filtration after glaucoma surgery. The IOP was significantly lowered with a few numbers of postoperative complications and a dramatic reduction in glaucoma medication. Postoperative bleb management was simpler with less goniopuncture and needling of the filtering bleb and no need for further surgeries in the group of patients operated with Healaflow™.

Keywords: anterior segment • intraocular pressure • wound healing 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×